抗結核剤の副作用について

化療方式別にみた副作用の比較

抄録

We carried out investigations on side-effects manifested in 943 pulmonary TB patients admitted and treated with one of the following 5 regimens of tuberculosis chemotherapy in our hospital during the period from January to December, 1974.
39% of primary cases were treated with SM·EINH·ERFP regimen, 25% with SM·INH·EPAS and 18% with SM·INH·EEB regimens, respectively. Among re-treatment cases, 26% were on the four-drug-combination of KM·RFP·INH·EB, and 20% on RFP·EINH·EEB.
As for the incidence of side-effects, SM·INH·EPAS group showed a highest frequency of 54%, and among these cases one or more of the combined drugs had to be discontinued in 43% due to side-effects. In the SM·EINH·ERFP group side-effects occurred in 41%, and a part or all of the combined drugs had to be discontinued in 20%. In re-treatment cases, side-effects were observed in 49% of the KM·ERFP·EINH·EEB group, and drugs had to be discontinued in 26%. Among the RFP·EINH·EEB group, side-effects occurred in 42%, but drugs had to be discontinued in only 15% which was the lowest percentage of all groups.
83 to 98% of side-effects occurred during the initia1 2 months of therapy in each group.
In primary treatment cases, side-effects occurred among patients with light body weight, in all the treatment groups, while no correlation was observed between the body weight and the incidence of side-effects in re-treatment cases.